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AbstrAct
Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal 
adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are 
frequently overexpressed in PDAC and correlate with aggressive tumor phenotype 
and poor prognosis. We evaluated the improvement in nab-paclitaxel response 
by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in 
preclinical PDAC models. In subcutaneous xenografts using AsPC-1 cells, average 
net tumor growth in different therapy groups was 248.3 mm3 in controls, 42.4 mm3 
after nab-paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 0.01) and 1.9 
mm3 after nab-paclitaxel plus BMS-754807 (p = 0.0002). In subcutaneous xenografts 
using Panc-1 cells, average net tumor growth in different therapy groups was: 294.3 
mm3 in controls, 23.1 mm3 after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS-
754807 (p = 0.02) and -87.4 mm3 (tumor regression) after nab-paclitaxel plus BMS-
754807 (p = 0.0001). In peritoneal dissemination model using AsPC-1 cells, median 
animal survival was increased compared to controls (21 days) after therapy with 
nab-paclitaxel (40 days, a 90% increase, p = 0.002), BMS-754807 (27 days, a 29% 
increase, p = 0.01) and nab-paclitaxel plus BMS-754807 (47 days, a 124% increase, 
p = 0.005), respectively. Decrease in proliferation and increase in apoptosis by nab-
paclitaxel and BMS-754807 therapy correlated with their in vivo antitumor activity. 
In vitro analysis revealed that the addition of IC25 dose of BMS-754807 decreased the 
nab-paclitaxel IC50 of PDAC cell lines. BMS-754807 therapy decreased phospho-IGF-
1R/IR and phospho-AKT expression, and increased cleavage of caspase-3 and PARP-1. 
These results support the potential of BMS-754807 in combination with nab-paclitaxel 
as an effective targeting option for pancreatic cancer therapy.
INtrODUctION
Pancreatic ductal adenocarcinoma (PDAC) is 
the fourth most common cause of cancer-related deaths 
in developed countries [1]. Surgical resection remains 
the best chance of long-term survival for patients 
with apparently localized PDAC. However, despite 
most advanced surgical techniques and antineoplastic 
combination treatments for advanced PDAC, the overall 
5-year survival still remains low at 6% [2]. PDAC is 
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expected to become the second-leading cause of cancer 
death by 2030, due to an increasing incidence and 
currently limited options to improve overall survival 
[3]. Less than 20% of PDAC patients are amenable to a 
curative surgical resection due to late clinical presentation, 
and early and aggressive local and metastatic progression 
[4]. Furthermore, even among these patients, postoperative 
recurrence remains commonplace [5, 6], leading to a 
5-year survival at less than 20% [7]. Therefore, in recent 
years much attention has been directed toward improving 
systemic treatment options for PDAC. Gemcitabine, a 
nucleoside analog, has limited clinical benefits but it 
remained a standard treatment for locally advanced and 
metastatic PDAC since 1997 after producing a response 
rate of 5% and a median survival of 5.7 months [8]. 
FOLFIRINOX, a combination of chemotherapy agents 
(oxaliplatin, irinotecan, 5-FU/leucovorin), nearly doubled 
the median survival of PDAC patients (11.1 months 
compared with 6.8 months in the gemcitabine group), but 
this regimen is highly toxic with serious side effects [9]. 
Nab-paclitaxel (NPT), a water-soluble albumin-bound 
paclitaxel, has recently shown efficacy against advanced 
PDAC [10, 11], and nab-paclitaxel in combination with 
gemcitabine demonstrated 8.5 months median survival 
compared with 6.7 months after gemcitabine alone [12]. 
Considering these trial-based moderate improvements in 
PDAC prognosis, there is an urgent requirement for novel 
therapeutic strategies to improve overall patient survival.
PDAC progression is a multifactorial process, 
with overexpression of several growth factors and their 
receptors including epidermal growth factor (EGF), 
fibroblast growth factor (FGF), platelet-derived growth 
factor (PDGF), vascular endothelial growth factor (VEGF) 
and insulin-like growth factor (IGF), being associated with 
the highly aggressive nature of PDAC [13, 14]. The IGF 
signaling axis mainly consists of ligands IGF-1, IGF-2, 
insulin and IGF-1 receptor (IGF-1R), insulin receptor (IR) 
and hybrid receptors. IGF-1R is the primary mitogenic 
receptor of the IGF system that is overexpressed and has 
increased tyrosine kinase activity in several cancer types 
including PDAC [14-16]. Most of the tumorigenic effects 
of IGF signaling involves the binding of two ligands, 
IGF-1 and IGF-2, to IGF-1R, leading to the activation 
of several downstream signal transduction pathways 
including the phosphatidylinositol 3’-kinase (PI3K)/AKT 
and mitogen-activated protein kinase (MAPK) pathways 
[17]. Aberrant IGF signaling stimulates proliferation, 
differentiation, angiogenesis, metastasis, survival, and 
drug resistance in many cancers [18, 19], establishing 
this pathway as a generally promising therapeutic target. 
The IGF-1R pathway inhibition has been the subject of 
intensive anti-cancer drug discovery efforts and currently 
there are more than 30 active clinical trials evaluating 
anti-IGF-1R targeting agents, either alone or in various 
combinations (www.clinicaltrial.gov). 
Three main strategies were employed to target the 
IGF pathway: monoclonal antibodies against IGF-1R, 
monoclonal antibodies against IGF-1R ligands (IGF-1 
and IGF-2), and IGF-1R tyrosine kinase inhibitors. IGF-
1R shares significant structural homology with IR, and 
targeting IGF pathway with IGF-1R inhibitor antibodies 
is sensible as it only blocks IGF-1R induced mitogenic 
signaling but is not affecting IR signaling, which could 
lead to dysregulation of glucose homeostasis [20, 21]. 
IGF-1R antibodies demonstrated clinical activity in phase 
2 studies in small number of patients with select tumor 
types including Ewing sarcoma, thymoma and thymic 
carcinoma [22-24]. However, many clinical trials with 
IGF-1R inhibitors failed to show any significant clinical 
benefit including hepatocellular carcinoma [25], non-small 
cell lung cancer [26] and breast cancer [27]. In pancreatic 
cancer, the combination of gemcitabine and ganitumab, 
a monoclonal antibody against IGF-1R, showed a 
significant clinical response in a phase 2 randomized trial 
[28], but unfortunately this combination did not show 
any clinical benefit in phase 3 evaluation [29]. Recently, 
a clinical study demonstrated a correlation between IGF-
1R signaling and tumor aggressiveness in PDAC patients 
[15], and increased exposure to ganitumab was found to be 
associated with improved overall survival and progression 
free survival in metastatic PDAC [30]. These findings 
demonstrate that IGF-1R remains a valid target for PDAC 
therapy.
Tyrosine kinase inhibitors can more indiscriminately 
regulate the kinase domain activity of all IGF system 
receptors as their primary sequence share 84% homology 
in the kinase domain with near complete conservation in 
the ATP binding pocket [31]. BMS-754807 (Supplemental 
Figure S1) is a potent and reversible inhibitor of IGF-1R/
IR (IC50 1.8 nM/1.7 nM), which also has more limited 
activity toward other kinases including Met, Aurora A/B, 
TrkA/B, Ron, Flt3, Lck, MK2, PKA and PKC [32, 33]. 
BMS-754807 has shown antitumor activity in a broad 
range of tumor types and it also enhanced antitumor 
response of other agents [33-36]. Recently, predictive 
biomarkers, including overexpression of IGF-1R, and 
KRAS and BRAF mutation status have been delineated for 
effectiveness of BMS-754807 [37]. In the present study, 
augmentation of response to nab-paclitaxel was evaluated 
by inhibition of IGF signaling in robust preclinical models 
of PDAC in an attempt to identify the efficacy of a novel 
therapeutic strategy.
rEsULts
Nab-paclitaxel and the IGF signaling inhibitor 
reduce the growth of PDAc xenografts
In the human subcutaneous PDAC xenografts, 
treatment of tumor-bearing mice with nab-paclitaxel 
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and BMS-754807, an inhibitor of IGF signaling, caused 
significant antitumor effects as mono- and combination 
therapy of these agents demonstrated additive effects. 
In subcutaneous xenografts using AsPC-1 cells, nab-
paclitaxel and BMS-754807 both caused a reduction in 
tumor growth while a combination of these two agents 
had additive effects (Figure 1A). Average net tumor 
growth, calculated by subtracting tumor volume on first 
therapy day from that on the last day, in different therapy 
groups was 248.3 mm3 in controls, 42.4 mm3 after nab-
paclitaxel (p = 0.002), 93.3 mm3 after BMS-754807 (p = 
0.01) and 1.9 mm3 after nab-paclitaxel plus BMS-754807 
(p = 0.0002) (Figure 1B). At completion of therapy, 
mean tumor weight in different therapy groups was 
0.33±0.19 g in controls, 0.14±0.08 g in nab-paclitaxel, 
0.18±0.04 g in BMS-754807 and 0.07±0.03 g in nab-
paclitaxel+BMS-754807 (Figure 1C). Furthermore, no 
significant change in total body weight was observed for 
those mice treated with nab-paclitaxel, BMS-754807 or 
combination (Figure 1D). In another subcutaneous PDAC 
xenograft experiment using Panc-1 cells, nab-paclitaxel 
and BMS-754807 treatment also caused a reduction 
in tumor growth with additive effects in combination 
(Figure 2A). Average net tumor growth in different 
therapy groups was 294.3 mm3 in controls, 23.1 mm3 
after nab-paclitaxel (p = 0.002), 118.2 mm3 after BMS-
754807 (p = 0.02) and -87.4 mm3 (tumor regression) after 
nab-paclitaxel plus BMS-754807 (p = 0.0001) (Figure 
2B). Mean tumor weight in different therapy groups was: 
0.30±0.06 g in controls, 0.16±0.05 g in nab-paclitaxel, 
0.22±0.02 g in BMS-754807 and 0.07±0.03 g in nab-
paclitaxel+BMS-754807 (Figure 2C). Also, no significant 
change in total body weight was observed for those mice 
treated with nab-paclitaxel, BMS-754807 or combination 
(Figure 2D).
Figure 1: Antitumor activity of nab-paclitaxel and bMs-754807 in AsPc-1 tumor xenografts. AsPC-1 cells were 
subcutaneously injected in nude mice and treated with nab-paclitaxel and BMS-754807 for 2 weeks. Tumor volume was measured twice a 
week using calipers. A. Relative tumor volume is calculated by dividing the tumor volume at any time by the tumor volume at the start of 
treatment. b. Net tumor growth was calculated by subtracting tumor volume on the first treatment day from that on the final day. c. Mean 
tumor weight was calculated from final day tumor weights in each group and is presented as a box plot. Box height denotes interquartile 
range; horizontal line within the box denotes median; and whiskers represent minimum and maximum values. D. Mouse body weight 
was measured twice a week and presented as bar chart for the 2-week therapy period. Data are representative of mean values ± standard 
deviation from 6-8 mice per group.
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Nab-paclitaxel and the IGF signaling inhibitor 
improve animal survival
In the human PDAC peritoneal dissemination model 
using AsPC-1 cells in NOD/SCID mice, nab-paclitaxel 
and BMS-754807 therapy was started two weeks after 
tumor cell injection and was continued for the subsequent 
two weeks (Figure 3A). Animal survival in different 
therapy groups, calculated from the start of therapy, was as 
follows: controls (21 days), nab-paclitaxel (40 days, a 90% 
increase compared with controls, p = 0.002), BMS-754807 
(27 days, a 29% increase compared with controls, p = 
0.01) and nab-paclitaxel+BMS-754807 (47 days, a 124% 
increase compared with control, p = 0.005) (Figure 3B). 
There was no significant change in mouse body weight 
during two week therapy period in all groups, indicating 
that there was no significant drug-related toxicity in 
monotherapy or combination therapy groups. 
Effects of nab-paclitaxel and the IGF signaling 
inhibitor on intratumoral proliferation and 
apoptosis
Possible mechanisms for the antitumor activities 
of nab-paclitaxel and BMS-754807 were investigated by 
IHC analysis of tumor tissues obtained from subcutaneous 
xenograft studies after completion of two weeks of 
therapy. 
Intratumoral proliferative activity was analyzed by 
Ki67 staining and this analysis demonstrated that nab-
paclitaxel and BMS-754807 inhibited intratumoral cell 
proliferation and combination therapy group generated 
additive effects. Different therapy groups showed the 
Figure 2: Antitumor activity of nab-paclitaxel and bMs-754807 in Panc-1 tumor xenografts. Panc-1 cells were 
subcutaneously injected in nude mice and treated with nab-paclitaxel and BMS-754807 for 2 weeks. Tumor volume was measured twice a 
week using calipers. A. Relative tumor volume is calculated by dividing the tumor volume at any time by the tumor volume at the start of 
treatment. b. Net tumor growth was calculated by subtracting tumor volume on the first treatment day from that on the final day. c. Mean 
tumor weight was calculated from final day tumor weights in each group and is presented as a box plot. Box height denotes interquartile 
range; horizontal line within the box denotes median; and whiskers represent minimum and maximum values. D. Mouse body weight 
was measured twice a week and presented as bar chart for the 2-week therapy period. Data are representative of mean values ± standard 
deviation from 6-8 mice per group.
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following intratumoral proliferative indices, calculated 
by percentage of Ki67-positive cells over total number 
of cells per HPF: controls (42.5±15.2), nab-paclitaxel 
(24.1±4.7), BMS-754807 (19.9±10.8) and nab-
paclitaxel+BMS-754807 (9.3+4.1) (Figure 4A).
Intratumoral apoptosis, measured by TUNEL 
assay, revealed that the nab-paclitaxel and BMS-
754807 monotherapy increased intratumoral apoptosis 
that was further increased in the combination therapy 
group. The apoptotic index, calculated by number of 
TUNEL-positive cells over total number of cells per 
HPF, in these therapy groups: controls (0.02±.01), nab-
paclitaxel (0.08±0.02), BMS-754807 (0.08±0.02) and nab-
paclitaxel+BMS-754807 (0.15±0.05) (Figure 4B). 
Additional mechanisms of in vivo antitumor activity 
of nab-paclitaxel and BMS-754807 were examined by 
analyzing intratumoral expression of their molecular 
targets by Western blot analysis. BMS-754807 therapy 
caused a significant decrease in the expression of 
phospho-IGF-1R/IR, and decreased the expression of 
the downstream signaling proteins phospho-AKT and 
phospho-ERK. Furthermore, BMS-754807 treatment 
caused a concomitant increase in the apoptosis marker 
proteins cleaved caspase-3 and cleaved PARP-1 (Figure 
5). 
Effects of nab-paclitaxel and the IGF signaling 
inhibitor on PDAc cell proliferation and cellular 
targets in vitro
The antitumor mechanism of nab-paclitaxel and 
BMS-754807 was evaluated by analyzing in vitro cell 
viability of human PDAC epithelial cells with different 
mutation status. Both, nab-paclitaxel and BMS-754807, 
inhibited PDAC cells proliferation. The combination 
treatment benefits of nab-paclitaxel and BMS-754807 
were observed by adding the IC25 dose of BMS-754807 
with increasing doses of nab-paclitaxel. Addition of BMS-
754807 decreased the nab-paclitaxel IC50 from 7.2 μM to 
490 nM for AsPC-1, 430 nM to 50 nM for BxPC-3, 740 
nM to 540 nM for MIA PaCa-2, and 690 nM to 280 nM 
for Panc-1 cell lines (Figure 6). Immunoblot analysis to 
determine the effect of the IGF signaling inhibitor on the 
IGF/receptor axis in AsPC-1 and Panc-1 cells, revealed 
that BMS-754807 blocked the expression of phospho-
IGF-1R/IR. BMS-754807 treatment also decreased the 
expression of downstream signaling protein phospho-
AKT but there was no significant effect on phospho-ERK 
expression. Nab-paclitaxel and BMS-754807 induced the 
expression of apoptosis-related cleaved caspase-3 protein, 
while combination treatment generated an additive effect 
(Figure 7). 
Figure 3: Improvement in animal survival by nab-paclitaxel and bMs-754807. A. Schematic representation of experimental 
procedure. AsPC-1 cells (0.75 x 106) were injected intraperitoneally in NOD/SCID mice and treatment started after 2 weeks with nab-
paclitaxel and BMS-754807 for 2 weeks. b. The curve represents the animal survival time from the beginning of therapy. Statistical group 
differences in survival time were calculated using logrank testing (GraphPad Prism 6.0). 
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DIscUssION
Activation of the IGF signaling pathway appears 
to be an important mechanism for progression of 
several malignancies. IGF-1R overexpression has been 
correlated with tumor aggressiveness [43-45] while 
disruption of IGF-1R activation inhibited growth and 
motility of a wide range of cancers [46]. Additionally, 
the blockage of IGF-1R signaling has been shown to 
enhance chemotherapy response in preclinical studies of 
several cancer types including pancreatic and non small-
cell lung cancers as well as Ewing’s sarcoma [43, 47, 48]. 
Since IGF-1R and IR are highly homologous, antagonist 
development was initially focused towards monoclonal 
antibodies that selectively target IGF-1R and not affect IR 
signaling, which could lead to dysregulation of glucose 
homeostasis [21]. Initial clinical studies with IGF-1R 
antibodies showed some responses in monotherapy and in 
combination with cytotoxic chemotherapy [49]. However, 
patients receiving antibody therapy have hyperglycemia 
Figure 4: Mechanisms of antitumor activity of nab-paclitaxel and bMs-754807. Nude mice were subcutaneously injected with 
AsPC-1 cells and treated with nab-paclitaxel and BMS-754807 for 2 weeks. A. Intratumoral proliferation was measured by immunostaining 
tissue sections for Ki67 nuclear antigen. Ki67-positive cells were counted in five different high power fields. b. Intratumoral apoptosis was 
measured by staining tumor tissue section with TUNEL procedure. TUNEL-positive apoptotic cells were counted in five different high 
power fields. For both immunostaining experiments, slides were photographed under a fluorescent microscope and the data are expressed 
as the mean ± standard deviation. 
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indicating the potential of undesirable metabolic side 
effects of such therapy [50]. Several reports showed the 
involvement of stimulation of IR by insulin or IGF-2 
in cancer cell progression [51, 52] suggesting that IGF-
1R and IR both are therapeutic targets and inhibition of 
both receptors may be required for optimal tumor growth 
inhibition. In PDAC specifically, the IGF signaling 
activation has also been shown to play a major role in 
tumor progression [14-16]. In addition, a recent study 
demonstrated a correlation between IGF-1R signaling 
and tumor aggressiveness in PDAC patients [15]. Based 
on these aspects and given the recent clinical progress in 
PDAC cytotoxic therapy, our present study thus explored 
the effects of BMS-754807, a small molecule inhibitor of 
both the receptors IGF-1R/IR, in combination with the 
recently approved and more effective chemotherapeutic 
agent nab-paclitaxel.
In multiple PDAC epithelial cells, we observed a 
differential expression of phosphorylated form of IGF-
1R/IR (Supplemental Figure S2), which is consistent 
with a previously published study [14], indicating a 
possible involvement of aberrant IGF signaling in PDAC 
progression. The IGF signaling inhibitor BMS-754807 
has shown antitumor activity in multiple tumor models 
including epithelial, mesenchymal and hematopoietic 
cancer cells [33]. We observed the effect of BMS-754807 
in subcutaneous xenografts using two aggressive PDAC 
cell lines, AsPC-1 and Panc-1. In these models, BMS-
754807 inhibited tumor growth as a single agent and more 
importantly, caused additive effects in combination with 
nab-paclitaxel. Analysis of intratumoral proliferation 
and apoptosis appear to be correlated with tumor growth 
inhibition data. Evaluation of target proteins in tumor 
lysates showed that BMS-754807 treatment decreased 
levels of the activated form of IGF-1R/IR and downstream 
effectors AKT and ERK, and induced levels of the 
apoptosis related proteins cleaved caspase-3 and cleaved 
PARP-1, indicating that the BMS-754807 therapy is 
Figure 5: Nab-paclitaxel and bMs-754807 effects on the IGF signaling pathways and apoptosis-related proteins in 
vivo. Tumor lysates were prepared from tumor tissues obtained from AsPC-1 tumor-bearing mice and were analyzed by immunoblotting. 
Data are representative of pooled lysates obtained from tumor sections of at least 5 mice in each therapy group. The intensity of bands was 
quantitated by densitometry and is represented in the bar graph after normalizing values with corresponding total protein expression or 
GAPDH expression. 
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indeed managing to sufficiently affect these targets within 
the local tumor model. Furthermore, BMS-754807 and 
nab-paclitaxel demonstrated a significant additive response 
to improve animal survival as evaluated in a peritoneal 
dissemination model using AsPC-1 cells which is highly 
reproducible, well characterized and closely resembles 
the metastatic progression pattern of the clinical disease. 
In the present study, we have not analyzed the effect of 
dosing schedule of the drugs where nab-paclitaxel was 
given prior to BMS-754807 to evaluate nab-paclitaxel 
induced tumor permeability. However, in the present study 
dosing schedule, nab-paclitaxel (twice per week) and 
BMS-754807 (five times per week) were given together 
on day 1; therefore, for all other doses of BMS-754807, 
nab-paclitaxel effects on tumor permeability might already 
be in place. 
BMS-754807 inhibited the proliferation of all 
PDAC cells tested; importantly, in all cell lines addition 
of IC25 dose of BMS-754807 decreased the IC50 values 
of nab-paclitaxel. Additionally, in AsPC-1 and Panc-1 
PDAC epithelial cells, BMS-754807 treatment caused a 
decrease in phosphorylated IGF-1R/IR and its downstream 
signaling protein phospho-AKT, no significant change 
in phospho-ERK, but increased cleavage of apoptosis 
related caspase-3 protein. A possible explanation for 
BMS-754807 to block ERK phosphorylation in AsPC-1 
tumor lysates but not in AsPC-1 or Panc-1 cell lines is 
the significant activity of stromal cells within tumors, 
in which ERK-phosphorylation has been shown to be 
blocked by BMS-754807 (own data, not shown here). A 
combination of these molecular signaling changes are thus 
likely operational in the BMS-754807 induced inhibition 
in cell proliferation and induction in apoptosis, and appear 
to represent good markers of in vivo activity testing and 
for clinical validation. 
Active PDAC progression involves multiple 
distinct mechanisms including induction in cancer cell 
proliferation, migration, differentiation, angiogenesis and 
inhibition of cancer or stromal cell apoptosis. Previous 
studies in our lab have shown the benefits of targeting 
multiple pathways in different cellular compartments 
including epithelial, vascular and stromal elements 
for PDAC treatment [39, 40, 42, 53]. Nab-paclitaxel 
itself has antiproliferative and proapoptotic effects on 
tumor cells, endothelial cells and fibroblasts. The exact 
molecular mechanisms for the enhancement in antitumor 
activity of nab-paclitaxel by BMS-754807 addition is not 
completely clear, but additive benefits are likely caused 
Figure 6: Addition of bMs-754807 had additive effects in combination with nab-paclitaxel to inhibit in vitro cell 
proliferation of PDAc cells. PDAC cells were plated on 96-well plates and treated with nab-paclitaxel (0 to 10 μM) as depicted through 
the open circle line. Another group of cells were treated with IC25 dose of BMS-754807 (500 μM) and nab-paclitaxel as depicted through 
the open triangle line. After 72 hours, 10 μl WST-1 reagent was added in each well and incubated for 2 additional hours. The absorbance 
at 450 nm was measured using a microplate reader. The resulting number of viable cells was calculated by measuring absorbance of color 
produced in each well. Data are the mean ± SD of triplicate determinations. 
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by augmentation of antiproliferative and proapoptotic 
activities and possibly not just restricted to the tumor 
cells of epithelial origin. Because of the multifactorial 
nature of PDAC and limited effectiveness of standard 
chemotherapy agents, combination therapies targeting 
multiple pathways represent sensible strategies for clinical 
evaluation. Based on our findings the combination of nab-
paclitaxel and BMS-754807 is a reasonable clinical trial 
option for phase II evaluation after establishing toxicity of 
this combination. 
Of note, most of the negative clinical trials of the 
IGF signaling inhibitors used monoclonal antibodies 
specifically targeting IGF-1R and not IR [25-27]. This 
could have potentially provided escape mechanisms for 
insulin and IGF-2 signaling that have been implicated in 
cancer cell progression [51, 52], leading to limited clinical 
response. Therefore, simultaneous inhibition of IGF-1R 
and IR by BMS-754807 may confer a better antitumor 
effect. Results from our prior work with BMS-754807 and 
gemcitabine as single cytotoxic agent in preclinical PDAC 
therapy would certainly support this broader targeting 
approach [36]. PDAC is histologically characterized by 
a dense desmoplastic reaction surrounding malignant 
epithelial cells that plays a critical role in tumor 
progression, invasion, metastasis and drug-resistance 
by providing a mechanical barrier. Nab-paclitaxel has 
Figure 7: Nab-paclitaxel and bMs-754807 effects on the IGF signaling pathway and apoptosis-related proteins. A 
sub-confluent monolayer of human PDAC cells AsPC-1 and Panc-1 was treated with nab-paclitaxel (10 μM) and BMS-754807 (10 μM), 
either alone or in combination for 16 hours. Total cell extracts were analyzed by immunoblotting. The intensity of bands was quantitated 
by densitometry and is represented in the bar graph after normalizing values with corresponding total protein expression or GAPDH 
expression. Data are representative of two independent experiments with similar results.
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been proposed to disrupt the PDAC stromal architecture, 
causing increased perfusion and drug-delivery [12]. Our 
laboratory has shown that the nab-paclitaxel is the most 
effective single agent cytotoxic agent in comparison with 
gemcitabine or docetaxel [10]. In addition, nab-paclitaxel 
combination with targeted therapies has been shown to 
efficiently improve antitumor response [11, 54]. Therefore, 
the application of combination therapy benefits of nab-
paclitaxel with BMS-754807 seems particularly logical 
and plausible for advanced PDAC.
Since BMS-754807 inhibits both IGF-1R and IR 
signaling, dysregulation of glucose homeostasis is an 
important concern, and therefore the advantage of its 
antitumor effects might have to be balanced with the 
potential for metabolic side effects. In our studies, there 
was no apparent in vivo toxicity during a 2-week treatment 
course, however, toxicity for long-term inhibition of the 
IGF-1R and IR functions remains to be elucidated. A 
previous study reported only a short-term increase in 
serum glucose or insulin levels at doses up to 12.5 mg/
kg, with an average weight change of -1.5 grams at 25 
mg/kg, but no mortality [33]. In our study, no significant 
change in mouse body weight was observed by BMS-
754807 therapy, but blood glucose measurements were 
not obtained. In conclusion, our study indicates that the 
combined IGF-1R/IR signaling inhibitor, BMS-754807, 
can mediate mechanism-specific antitumor activity in 
experimental PDAC, and significantly improves nab-
paclitaxel response. These findings corroborate the 
rationale of blocking multiple pathways of the IGF and 
insulin signaling, and support the potential of BMS-
754807 as targeting agent for clinical PDAC therapy.
MAtErIALs AND MEtHODs
cell culture and reagents
Human PDAC cell lines (AsPC-1, BxPC-3, Mia 
PaCa-2 and Panc-1) were purchased from the American 
Type Culture Collection (ATCC, Rockville, MD). Cell 
lines were tested and authenticated by ATCC. Cells were 
initially grown and multiple aliquots were cryopreserved. 
All the cell lines were used within 6 months after 
reexpansion in culture. Cells were cultured in DMEM 
or RPMI 1640 medium (Sigma Chemical Co. St. Louis, 
MO) containing 10% FBS and maintained at 37°C in a 
humidified incubator with 5% CO2 and 95% air. BMS-
754807 was purchased from Active Biochem (Maplewood, 
NJ). The cell proliferation reagent WST-1 was purchased 
from Roche Diagnostic Corporation (Indianapolis, IN). 
Western blot analysis
PDAC cells were treated with nab-paclitaxel 
(10 μM) and BMS-754807 (10 μM), and lysed after 16 
hours to prepare cell lysate for Western blotting. Tumor 
lysates were prepared by snap freezing tumor tissues in 
liquid nitrogen and stored at -80°C. These tumor tissues 
were suspended in lysis buffer and homogenized using 
the Bullet Blender Homogenizer (Next Generation, 
Averill Park, NY), and extracts were sonicated on ice. 
Proteins in supernatants were separated by SDS-PAGE 
and transferred to PVDF membranes (Bio-Rad, Hercules, 
CA). The membranes were incubated overnight at 4°C 
with the following antibodies: total IGF-1R, phospho-
IGF-1R (Tyr1135/1136)/IR (Tyr1150/1151; #3024), total 
AKT, phospho-AKT (Ser473), total ERK1/2, phospho-
ERK1/2 (Thr202/Tyr204), cleaved caspase-3, cleaved 
PARP-1 and GAPDH (Cell Signaling Technology, 
Beverly, MA). The membranes were then incubated with 
the corresponding HRP-conjugated secondary antibodies 
(Pierce Biotechnologies, Santa Cruz, CA) for 1 to 2 hour. 
Specific protein bands were visualized using the enhanced 
chemiluminescence reagent (SignalFire, Cell Signaling) 
with Image360 system and quantitated by densitometry.
cell viability assay
Cell viability of PDAC lines was evaluated by the 
colorimetric WST-1 assay as previously described [38]. 
Briefly, PDAC cells (4,000 cells per well) were plated 
in a 96-well plate in regular growth medium. After 16 
hours the medium was replaced with 2% FBS containing 
medium and the cells were treated with nab-paclitaxel (50 
nM to 10 μM) and IC25 dose of BMS-754807 (500 nM). 
After 72 hours, 10 μl WST-1 reagent was added in each 
well followed by additional incubation for 2 hours. The 
absorbance was measured at 450 nm using a microplate 
reader. 
Animal studies
All animals were housed in pathogen-free facility 
with access to food and water ad libitum. Animal 
experiments were performed in accordance with the 
Institutional Animal Care and Use Committee (IACUC) 
at the Indiana University School of Medicine (South 
Bend, IN). Female nonobese diabetic/severe combined 
immunodeficient (NOD/SCID) mice (4 to 6 weeks old) 
were subcutaneously injected with AsPC-1 cells (0.75 x 
106) or Panc-1 cells (10 x 106) as previously described 
[11]. Two weeks after tumor cell injection, all mice had 
measurable tumor. Mice were then randomized (n = 6 to 
8 per group) to receive PBS (control), nab-paclitaxel (10 
mg/kg, twice a week) and (BMS-754807 (25 mg/kg in 100 
Oncotarget46998www.impactjournals.com/oncotarget
ml PBS, 5 times a week) via intraperitoneal injection for 
2 weeks. The tumor size was measured twice weekly, and 
tumor volume (V) was calculated using the formula V = ½ 
(Length x Width2). Mice were euthanized after completion 
of treatment, tumors were dissected and processed for 
histological, immunohistochemical and Western blot 
analysis.
Animal survival studies were performed using 
female NOD/SCID mice (4-6 weeks of age) as previously 
described [39]. Briefly, the mice were intraperitoneally 
injected with AsPC-1 (0.75x106) cells and two weeks after 
tumor cell injection, mice were randomized (n = 6 to 8 per 
group) to receive PBS (control), nab-paclitaxel (10 mg/kg, 
twice a week) or BMS-754807 (25 mg/kg in 100 ml PBS, 
5 times a week) via IP injection for two weeks. Animals 
were euthanized when moribund according to predefined 
criteria [40, 41]. Animal survival was evaluated from the 
first day of treatment until death.
Immunohistochemistry and immunofluorescence 
Standard immunohistochemistry protocol was 
followed to stain the tumor tissue samples, as previously 
described [42]. Briefly, tumor tissue samples were fixed 
in 4% paraformaldehyde, embedded in paraffin, tissue 
sections were cut (5 μm), deparaffinized and rehydrated. 
The tissue sections were incubated with Ki67 antibody 
(1:200 dilution) followed by incubation with Cy3 (1:200 
dilution) secondary antibody. Slides were mounted 
using mounting solution containing 4’,6-diamidino-
2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). 
Intratumoral proliferative index was evaluated by 
calculating the Ki67-positive cells from five different 
high-power fields (HPF) in a blinded manner. Intratumoral 
apoptotic activity was evaluated by staining tissue sections 
with “Apoptag Apoptosis Detection Kit” according to the 
manufacturer’s (Millipore, Temecula, CA) instructions. 
Fluorescence microscopy was used to detect fluorescent 
signals using the IX81 Olympus microscope equipped 
with a Hamamatsu Orca digital camera (Hamamatsu 
Corporation, Bridgewater, NJ) and a DSU spinning 
confocal unit using Slidebook software (Intelligent 
Imaging Innovations, Philadelphia, PA).
statistical analysis
Statistical analysis for in vivo tumor growth studies 
was performed by one-way ANOVA for multiple group 
comparison and Student’s t-test for the individual group 
comparison. Survival study statistics were performed 
using logrank group comparison (GraphPad Prism 6.0). 
P values less than 0.05 were considered statistically 
significant. In vitro cell proliferation data are expressed 
as mean ± standard deviation. Statistical significance was 
analyzed by the two-tailed Student’s t-test using GraphPad 
Prism 6.0 Software (GraphPad Software, San Diego, CA) 
for individual group comparisons. 
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